Thymus-derived murine cytotoxic effector cells generated to viral or chemically modified autologous cells have been shown to selectively lyse target cells expressing the same H-2 serological regions as the stimulator cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . In vivo, the cytotoxic effectors generated to lymphocytic choriomeningitis (LCM) 1 (2, 3, 5) , ectromelia (4), or vaccinia (8) viral-infected autologous components were demonstrated to be specific only for target cells expressing in common with the stimulator cell at least one H-2 serological region (2) (3) (4) (5) 8) and infected with the same or a cross-reacting virus (8) . In vitro, cell-mediated lympholysis (CML) reactions were generated by sensitization with trinitrophenyl (TNP)-modified autologous spleen cells (1, 6, 7) . Splenic target cells were lysed by the effectors only if they were homologous with the stimulating cells at the K and/or D regions of H-2, and if they were modified with TNP (1, 6, 7, 9) .
Since a number of viruses have now been shown to elicit cytotoxic reactions with this type of H-2 and viral-associated specificity, it was of interest to determine whether other modifying agents known to possess haptenic functions in antibody production would stimulate cytotoxic effector cells with similar specificity requirements. The modifying agent N-(3-nitro-4-hydroxy-5-iodophenylacetyl)-13-alanylglycylglycyl-(N) was chosen for this study since Koren et al. have demonstrated that cytotoxic T-effector cells can be generated in vitro to Nmodified, H-2-matched autologous spleen cells (11) . The results presented in this report demonstrate that the cytotoxic effector cells generated in vitro by sensitization to N-modified autologous spleen cells are specific for N-modified target cells expressing K and/or D serological specificities identical to those of the modified stimulating cells. Similar to the observations made in the autologous TNP-modified model (6, 7, 9), the CML generated in certain strains were stronger to N-modified K than to N-modified D-region products, although the strain distribution patterns of preferential reactivity were different for the N and TNP models. Specificity for the modifying agent as well as for H-2K-and/or H-2D-region products was also demonstrated.
Materials and Methods
Mice. All mice used in these experiments were 7-9-wk-old males. The B10 congenic strains were obtained from The Jackson Laboratory, Bar Harbor, Maine. The B10.A(2R), B10.A(4R), and B10.A(5R) recombinant strains were obtained either from The Jackson Laboratory or were raised in our mouse colony from breeders obtained from The Jackson Laboratory or from Dr. Donald Shreffler, Department of Human Genetics, University of Michigan, Ann Arbor, Mich.
Tumor Cells. All tumors used in these experiments were serially passed at 7-9-day intervals in ascitic fluid. The tumors used and the strain in which each was passed were as follows: EL4 (/4-2 ~) in C57BL16; P815 (11-2 ~) 
N Modification of Spleen and Tumor Cells for Sensitization and Targets. Tumor cells were
obtained from the ascitic fluid of mice and filtered through nylon mesh to remove clumps. Fresh spleen cells were obtained from 7-9-wk-old male mice and suspended in Hanks' balanced salt solution (BSS) by gentle teasing with a blunt forceps. They were then aspirated through a syringe 3-4 times and filtered with nylon mesh. Erythrocytes were removed by suspension in ammonium chloride lysing solution (ACK) for 2 min. The lymphocytes were washed once in BSS and given a final wash in phosphate-buffered saline (PBS), pH 7.6. The stock reagent of N-azide was prepared as previously described (12, and footnote 2) and diluted to 0.04 M concentrations with dimethylformamide and stored at -50°C. For modification 15 ~1 of N azide, suspended in 0.25 ml PBS, pH 7.6, was added to the cell pellet which had previously been suspended in 1 ml PBS, pH 7.6. The cells were incubated for 20 min at 37°C in a shaking water bath. The cells were then washed two times in BSS with 10% fetal calf serum. Cells to be used as targets were labeled with Na~5~CrO4 (New England Nuclear, Boston, Mass.) for 30 min before either N or TNP modification by incubation in a 37°C water bath.
TNP Modification of Spleen and Tumor Cells.
Cell suspensions were prepared as described above except that the final wash after ACK lysing was in BSS. The cell pellet was then suspended in 2 ml of a phosphate-buffered solution of 10 mM 2,4,6-trinitrobenzene sulfonate (Pierce Chemical Co., Rockford, Ill.), pH 7.4, and incubated in a shaking water bath at 37°C for 10 min. The cell suspension was then washed twice in BSS supplemented with 10% fetal calf serum.
In Vitro Cell Culture and Assay for Cytotoxic Cells. Splenic lymphocytes were sensitized in vitro with N-or TNP-modified cells, as previously described for TNP (1) . The culture medium was RPMI 1640 (Microbiological Associates, Bethesda, Md.) supplemented with 10% fetal calf serum (Microbiological Associates), 2 mM L-glutamine (National Institutes of Health Media Unit), 1 mM pyruvate (Microbiological Associates), 1 x nonessential amino acids (Microbiological Associates), 100 U/ml penicillin, 100 ~g/ml streptomycin, and 5 × 10 -5 M 2-mercaptoethanol. After a 5-day incubation the cells were harvested and their cytotoxic activity measured as previously described (1) . The mean and standard error of the percentage of specific cytotoxicity was calculated as described elsewhere (13) . An effector target ratio of 40:1 was used except where noted. Nonspecific lysis of modified cells was determined from the amount of 51Cr released from the appropriate 5~Cr-labeled target cells incubated for 4 h with effector cells which were incubated 5 days with no stimulator cells divided by the maximal ~lCr release. Background lysis varied in these experiments from 15 to 50%.
Phytohemagglutinin (PHA) Stimulation of Spleen Cells.
A fresh spleen cell suspension was obtained by teasing the spleens with a blunt forceps, aspirating the cells through a syringe, and 2 Koren, H. S., J. R. Wunderlich, and J. K. Inman. 1975 . T cell memory for the cytotoxic response to hapten-modified target cells. Submitted for publication. then filtering the cells through nylon mesh. The cells were washed once in BSS before being suspended at a concentration of 5 × l0 s per ml in RPMI 1640 culture media supplemented as described above plus ~1 /~g/ml of PHA (Burroughs Welcome & Co., Greenville, N. C.). After incubation for 2, 3, or 4 days, the cells were harvested immediately before use as targets.
Results
Target Cell Sensitivity to Effectors Generated by Sensitization with N-Modified Autologous Spleen Cells. Earlier studies of CML to TNP-modified autologous spleen cells indicated that appreciable lysis could be detected to TNP modified tumor or TNP-modified H-2-matched normal spleen cell targets at effector:target ratios of 20:1 (1, 6) . However, at similar ratios, effector cells generated to N-modified syngeneic spleen cells were consistently detected using N-modified, H-2-matched tumor targets, but only occasionally when N-modified spleen cells were used as targets (11) . To investigate the relative sensitivity of various N-modified lymphoid targets, C57BL/10 and B10.BR splenic lymphocytes were sensitized to N-modified autologous spleen cells. The effector cells generated were assayed on N-modified fresh spleen cells, 48-72-h PHA-stimulated N-modified spleen cells, or N-modified lymphoid tumor cells, syngeneic or allogeneic to the responding and stimulating lymphocytes. The results, shown in with the cells of the stimulating phase were lysed, and that N-modified tumor cells and PHA-stimulated N-modified spleen cells were more effective targets than unstimulated N-modified spleen cells. In all subsequent experiments, spleen cell targets for CML were PHA-stimulated. 
Specificity of Effector Cells

Mapping of Effector Cell Specificity within the H-2 Complex. Previous
reports have demonstrated that in vitro induction of CML to TNP-modified autologous spleen cells resulted in the generation of effector cells which were specific for TNP-modified spleen target cells sharing K and/or D end serological specificities with the TNP-modified stimulator cells (6, 7, 9) . In the present study four C57BL/10 congenic mouse strains were used to determine whether similar H-2 serological region homology is required to obtain lysis of N-modified, PHAstimulated spleen targets. Splenic lymphocytes from B10.BR, B10.D2, B10.A, and C57BL/10 donors were sensitized to N-modified autologous spleen cells. The effector cells generated after 5 days of culture were tested for lysis of syngeneic, congenic, and allogeneic N-modified, PHA-stimulated spleen target cells. Results representative of these effector cell specificity experiments are summarized in Tables III-VI of this report. The first three columns of these tables indicate the strains of the responding, stimulating, and target cells, respec- All of H-2
All of H-2
All of H-2 Representative data of CML experiments obtained using B10.BR effector cells generated by sensitization of splenic lymphocytes with B10.BR-N stimulating 
cells are summarized in Table III . Unmodified B10.BR target cells were not lysed by the effector cells, whereas N-modified syngeneic targets were lysed. Nmodified B10.A and B10.A(2R) spleen cells, which share K, I-A, and I-B H-2 regions with B10.BR were effective targets. The lysis of modified B10.A(4R) targets further localizes one area of homology to the K and I-A regions of H-2. The lower but significant lysis of the noncongenic C3H. OH-N targets by B10.BR effectors localizes a second region of H-2 homology to the D region of the major histocompatibility complex (MHC). The above results contrast to the modified congenic B10.D2 and B10.A(5R) targets, which were not lysed and which share no known major regions of H-2 homology with B10.BR responding and stimulating cells.
Effector cells generated from cultures of B10.D2 lymphocytes sensitized with B10.D2-N-modified spleen cells were also tested on a series of N-modified target cells. The results are shown in Table IV modified targets (see Table V targets (see Table VI autologous spleen cells, C57BL/10 responding lymphocytes generated effector cells with equal reactivity toward TNP-modified H-2K and TNP-modified H-2D serological region products (6) . In contrast, it was consistently found that C57BL/10 responding lymphocytes generated effector cells which exhibited greater reactivity to N-modified K-end than to N-modified D-end products (see Table VI ). Table VII compares the differential cytotoxic reactivity of C57BL/10 responding lymphocytes sensitized either with TNP-or N-modified autologous stimulating cells. These effector cells were assayed on target cells H-2 matched with the stimulating cell at the K or D end and modified with the same reagent to which the effector cell precursor had been stimulated. These results verify that equivalent cytotoxic reactivity was obtained to TNP-modified K-or Dregion products, whereas stronger lympholysis was detected to N-modified Kend products than to N-modified D-end products.
Specificity of Lympholysis as a Function of the Modifying Agent.
To determine whether the modifying agent plays a significant role in the specificity of the cytotoxic reaction to modified autologous spleen cells, responding lymphocytes from three B10 congenic mouse strains were sensitized to autologous spleen cells modified either with TNP or N. The effector cells generated in each sensitization were assayed separately on H-2-matched tumor targets modified with either TNP or N. The results, summarized in Table VIII, demonstrate that effector cells generated by sensitization with autologous spleen cells modified with one of the reagents lyse only H-2-matched targets modified with the same reagent. Thus, no cross-reactivity was detected for CML generated against TNP-modified and N-modified autologous spleen cells. Table X . These data confirm the results of the previous experiment, since the effector cells generated lysed RDM-4-N but not P-815-N target cells. In addition, an attempt was made to block the lytic phases with non-5'Cr-labeled modified and unmodified RDM-4 and P-815 cells. An appreciable reduction in lympholysis was observed only when the effectors were preincubated for 30 min with the Nmodified H-2-matched RDM-4 cells.
Demonstration that K and~or D Homology is Required between N-Modified Target and N-Modified Stimulating Cells. In the preceding four tables H-2
Discussion
The results presented in the first six tables of this report consistently demonstrated that the cytotoxic specificity of effector cells generated in a CML to Nmodified autologous spleen cells involved both H-2 serological region homology and N modification of both stimulating and target cells. By testing the effector cells on N-modified targets differing from the responding and stimulating cells within H-2, it was possible to identify two distinct H-2 regions in each inbred strain toward which the specificity was directed.
The mapping studies of effector cell specificity to N-modified autologous cells presented here are similar to those reported earlier using TNP-modified autologous cells (6, 9) . Effector cells from the B10.BR (Table III) and B10.A (Table V) strains sensitized to N-modified autologous spleen cells exhibited cytotoxic specificity to N-modified targets sharing K or K plus I-A with the cells of the stimulating phase. A significant but lower level of reactivity was generated to N-modified targets sharing H-2D in the case of B10.BR and to N-modified targets sharing alleles in the D half of H-2 in the case of B10.A. It is interesting that reactivity to N-modified targets sharing K end was greater than that to Nmodified targets sharing D end. This pattern of preferential reactivity to K end is similar to that observed for CML in these two strains to TNP-modified autologous stimulating cells (6, 9) . Respond-Stimulating cells ing cells .D2 effector cells were demonstrated to exhibit significant cytotoxicity toward N-modified targets sharing one or two H-2 regmns with the responding or stimulating cells (Table IV) . As shown by the use of N-modified recombinant congenic strains, the regions probably involved D alone and some regions not including D, presumably the K serological region as shown by the C3H.OH targets. Again, these B10.D2 data quantitatively resemble those obtained with TNP-modified autologous spleen cells in that equal cytotoxic reactivity was detected toward K or D-matched N-modified targets. The level of cytotoxicity of B10.D2 effector cells was lower than that generated by B10.BR and B10.A to their respective N-modified targets, as was seen in the TNP system (6, 9) .
Responder lymphocytes from C57BL/10 mice generated effector cells which lysed N-modified targets homologous with the cells of the stimulating phase at K, I-A, and I-B or at the D serological region (Table VI) . However, in contrast to the TNP-autologous CML in which C57BL/10 effector cells lysed equally well TNP-modified target cells matched at the K or D end with the cells of the sensitization phase (upper part of Table VII), the N-autologous CML in this strain lysed N-modified targets matched at the K end greater than N-modified targets matched at the D end (lower part of Table VII ). These differential patterns of reactivity could be due to differences in immunogenicity of the antigenic specificities associated with the K and D ends and/or to H-2-1inked immune response genes controlling reactivity to these specificities. The data presented in this study do not distinguish between these possibilities. A recently published report indicates that differential reactivities to TNP-modified K and D region products involves both immune response genes acting at the level of the responder lymphocytes and differential immunogenicity at the level of the stimulating cell (7). Studies using F1 and recombinant animals are currently in progress to investigate these possibilities in the N system. Since it was necessary to modify the target cells to obtain lysis by effector cells generated by chemically-modified autologous spleen cells (1, 6, 7, 9, 11 and Tables II-VI), the specificity requirements of the N and TNP modifying agents were investigated. The results of Table VIII demonstrate that effector cells generated by sensitization with TNP-modified autologous cells do not lyse Nmodified syngeneic targets and vice versa. These findings are compatible with one of three possibilities: (a) that "hapten specificity" is involved and that H-2 homology is required between effector and target cells by cell-to-cell interaction requiring H-2 identity possibly similar to that reported by Katz et al. for antibody production (14) ; (b) that these modifying agents induce distinct and specific conformational changes in the structure of rio2 serological region products, but do not themselves compose part of the antigenic structure; or (c) that TNP and N constitute integral components of a new antigen created by the modification that involves altered H-2 serological region products.
The possibility of a major "hapten-specific" CML with intra H-2 identity required for effector-target cell interaction can be excluded by the F1 data presented in Tables IX and X . If possibility (a) were correct, then F1 effector cells generated by sensitization with N-modified cells from either of the parents should have lysed N-modified targets from both parents. These findings demonstrate that intra-H-2 homology is required between N-modified stimulator and N-modified target cells, or among responding, stimulating, and target cells. This experimental design and the conclusions drawn are similar to other examples of CML to viral (3, 4, 8) -and chemically (6, 9)-modified autologous cell models.
While possibility (b) cannot be evaluated by data presented in this report, the observations that TNP-and N-modified chicken erythrocytes block effector cell lysis of the appropriate TNP-or N-modified target cells, respectively (15, and Koren, unpublished observations) suggest that these moieties may be integral components of new antigens created by modification of H-2 products. However, the demonstration that unmodified chicken red blood cells will not block while chemically-modified chicken red blood cells do block does not prove specificity. The blocking could be due to a nonspecific toxic effect of the modified chicken red blood cells. For instance, it must be shown that TNP chicken red blood cells do not block other cytolytic reactions such as an allogeneic CML or preferably a CML model more similar to the N system. Koren (manuscript in preparation) has found such controls difficult to obtain reproducibly. In contrast to modified chicken red blood cell blocking, inhibition with chemically-modified spleen cells occurs only when there is H-2 homology among stimulating, target, and blocking cells (6, and Table X) . It is not understood at the present time why H-2 homology is required for blocking of lysis by modified spleen cells, whereas no such homology appears to be necessary for blocking by modified chicken erythrocytes.
The data available in the N modification system as well as other systems (3, 4, 6, 8, 9, 16) are compatible with the hypothesis that certain viral and chemical agents can modify H-2-related cell surface components (possibly serological region products) to create new antigenic determinants. These "neo-self antigens" appear to include as part of the viral (3, 4, 6, 8, 16) or chemical (6, 9) recognition structure the respective modifying agent.
The (C57BL/10 × B10.BR)F1 responding lymphocytes sensitized to N-modified autologous F1 cells generated a broader range of effector cell specificities than would either of the homologous parents (Tables IX, III, VI) . If an expanded range of cytotoxic specificities were advantageous for survival, as might be expected in a viral model (17) , then a selective pressure for pelymorphism in the MHC would exist (6, 17) . Such a pressure could be exerted by functionally distinct H-2 products at the level of formation of the new antigen (modified serological region products) and/or at the level of response potential to that antigen (immune response genes). The C57BL/10 effector cells were shown to react to the K end greater than the D end, which differed from the equal reactivity seen in the TNP system for this strain. The data are consistent with the hypothesis that the antigen recognized by the effector cell includes an altered H-2 serological cell surface product. That the reaction is not "hapten specific" and the H-2 homology is required only for effector:target cell interaction was excluded by the use of two FI combinations in which lysis of only N-modified target cells sharing the H-2 haplotype with the stimulating parental strain was obtained. Finally, it was demonstrated that N and TNP modification create distinct new antigenic determinants, since an effector cell sensitized to one modifying agent will lyse only H-2-matched target modified with that same modifying agent.
